Analyst Price Target is $1.75
▲ +173.95% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Akebia Therapeutics in the last 3 months. The average price target is $1.75, with a high forecast of $2.00 and a low forecast of $1.25. The average price target represents a 173.95% upside from the last price of $0.64.
Current Consensus is
The current consensus among 6 polled investment analysts is to hold stock in Akebia Therapeutics. This Hold consensus rating has held steady for over two years.
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.